Results from a recent study of HIV-positive adults in Switzerland show that following United States antiretroviral therapy treatment guidelines when deciding on initial therapy regimens results in a greater likelihood of successfully suppressing HIV.

The researchers also found that the vast majority of patients receive regimens that conform to guideline recommendations.

The authors stated that their results validate the recommendations in current guidelines as well as the utility of the guides in helping clinicians decide on initial regimens to prescribe.

“Our results suggest that, in the context of constant increase…

This article is the second of a two-part series on a review of Reyataz-related treatments and side effects. The first part discusses recent results on simplified Reyataz-based antiretroviral regimens; the second part discusses side effects associated with Reyataz.

A review of results from several studies on Reyataz indicates that relative to other antiretrovirals, Reyataz may be associated with fewer side effects in certain areas – such as heart problems – but more in other areas, such as kidney problems.

Results also showed that Reyataz alone was able to control…

This article is the first of a two-part series on a review of Reyataz-related treatments and side effects. The first part discusses recent results on simplified Reyataz-based antiretroviral regimens; the second part discusses side effects associated with Reyataz.

A review of Reyataz-related studies at a recent conference suggests that simplified two-drug regimens using Norvir-boosted Reyataz may be as effective as three-drug regimens in patients with well-controlled HIV infection.

According to the review authors, the findings are exciting since treatment simplification and fewer side effects are likely to improve adherence…

This article is the second part of a two-part interview with Dr. Jeffrey Laurence, senior scientific consultant for the Foundation for AIDS Research, on the Foundation’s efforts toward a cure for HIV. Part 1 discusses the possibility of a cure and why it is necessary. Part 2 discusses the Foundation’s cure research and some promising avenues toward a cure.

Thirty years after the start of the AIDS epidemic, scientists and researchers know more than ever about the elusive and difficult-to-treat HIV virus. And, with the first-ever example of a…

This article is the first part of a two-part interview with Dr. Jeffrey Laurence, senior scientific consultant for the Foundation for AIDS Research, on the Foundation’s efforts toward a cure for HIV. Part 1 discusses the possibility of a cure and why it is necessary. Part 2 discusses the Foundation’s cure research and some promising avenues toward a cure.

When it was founded in 1985 by actress Elizabeth Taylor and scientist Mathilde Krim, the purpose of the Foundation for AIDS Research, known by its initials amfAR, was to…